N-(1-adamantan-2-yl)-4,5-dihydroxyoxazol-2-amine | 175898-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: N-(1-adamantan-2-yl)-4,5-dihydroxyoxazol-2-amine
• 英文别名: N-(2-adamantyl)-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 175898-10-9
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: CURQGMSZTYYKAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  33.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(2-金刚烷基)-3-(2-氯乙基)脲 在 KF on SiO₂ 作用下， 以 乙腈 为溶剂， 以98%的产率得到N-(1-adamantan-2-yl)-4,5-dihydroxyoxazol-2-amine
  参考文献：
  名称：

  Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression

  摘要：

  Recently, a subset of N-phenyl-N'-(2-chloroethyl) ureas (CEU) was found abrogating the nuclear translocation of thioredoxin-1 and arresting the cell cycle in G(0)/G(1) phase. Several derivatives were prepared to assess their effect on cell cycle progression and on the intracellular location of Trx-1. Compounds 1-20, 21-40, and 41-60 exhibited GI(50) between 1 and 80 mu M. Immunocytochemistry analysis showed compounds 4, 6, 8, 10, 11, 23, 24, 26-31, 34, 37, 41, 44, 46-51, 53, 56, and 57 inhibiting the nuclear translocation of Trx-1. Our results suggest that increasing the electrophilic character of these molecules might enhance the antiproliferative activity at the expense of the selectivity toward thioredoxin-1 and the G(0)/G(1) phase arrest. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.006

文献信息

• [EN] AGENTS FOR REVERSING TOXIC PROTEINOPATHIES<br/>[FR] AGENTS POUR INVERSER DES PROTÉINOPATHIES TOXIQUES
  申请人：BROAD INST INC

  公开号：WO2020257736A1

  公开（公告）日：2020-12-24

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.

  本公开涉及诊断和治疗或预防蛋白质病变的组合物和方法，特别是与MUC1相关的肾脏疾病（ADTKD-MUC1或MKD）、视网膜色素变性（例如由于视紫红质突变引起）、由UMOD突变引起的常染色体显性小管间质肾病（ADTKD-UMOD）以及由突变蛋白在内质网或其他分泌途径间室和/或囊泡中积累导致的其他形式的有毒蛋白病变等。本公开还确定并提供了TMED9结合剂，作为治疗或预防分泌途径蛋白病变的能力，并进一步提供了识别其他TMED9结合剂的方法。
• AGENTS FOR REVERSING TOXIC PROTEINOPATHIES
  申请人：The Broad Institute, Inc.

  公开号：EP3986412A1

  公开（公告）日：2022-04-27